ArcticZymes Technologies - Board/Management Information 2014

Biotec Pharmacon hires Børge Sørvoll as CFO

Biotec Pharmacon is pleased to announce that it has hired Børge Sørvoll

(38) as CFO. Sørvoll assumes the position on 1 October 2014, and will be

based at the company's headquarters in Tromsø.

Børge Sørvoll comes from the position as SCM Manager at Subsea 7, and

has previous experience as CFO in Front Exploration and as a CEO of

Troms Kraft Invest. Sørvoll holds a Master's Degree in Business and

Administration from the University of Wyoming.

- We are strengthening our organization to prepare for the

commercialization of Biotec BetaGlucans' Woulgan® Biogel as well as

continued growth for the enzyme portfolio in ArcticZymes. I am glad to

welcome Børge onboard and look forward to be working with him in

exciting times for Biotec Pharmacon, says CEO Svein Lien.

For more information, please contact:

CEO Svein W. F. Lien, tel +47 922 89 323

About Biotec Pharmacon ASA:

Biotec Pharmacon ASA is the parent company of Biotec BetaGlucans AS and

ArcticZymes AS. Biotec BetaGlucans develops and manufactures novel

immunomodulating products, and has recently obtained CE-mark for

Woulgan® Biogel containing its proprietary substance SBG®. Woulgan®

Biogel is a single-patient primary dressing for one-time use on skin

wounds, including diabetic ulcers, bedsores, leg ulcers, transplantation

wounds, post-surgery wounds, trauma wounds, first- and second-degree

burns, abrasions, and cuts. The company is currently performing a market

evaluation study in collaboration with world leaders Smith & Nephew.

ArcticZymes develops, produces and sells enzymes of marine origin used

in molecular DNA technologies and diagnostics, growth markets where

rapid technological developments are creating a strong demand for new

and improved enzymes.

AI assistant